Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 4/20 | 0.73 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29995811 | 1.00 | BCL2 (0.73) | BCL2BCL2L1 | |
| SCHEMBL29996194 | 0.97 | BCL2 (0.69) | BCL2 | |
| SCHEMBL26669760 | 0.97 | BCL2 (0.77) | BCL2 | |
| SCHEMBL29995342 | 0.97 | BCL2 (0.77) | BCL2 | |
| SCHEMBL26669791 | 0.97 | BCL2 (0.69) | BCL2 | |
| SCHEMBL29995221 | 0.94 | BCL2 (0.69) | BCL2 | |
| SCHEMBL26669887 | 0.94 | BCL2 (0.69) | BCL2 | |
| SCHEMBL26669881 | 0.91 | BCL2 (0.76) | BCL2BCL2L1 | |
| SCHEMBL26818423 | 0.91 | BCL2 (0.61) | BCL2 | |
| SCHEMBL26825392 | 0.89 | BCL2 (0.59) | BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043424-A1 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-02-08 | — | — | US | claimed |
| US-20240043424-A1 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-02-08 | — | — | US | disclosed |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | BCL2 1/4885BCL2L1 3/4885 |
| US-20240043424-A1 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | BCL2, BCL2A1, BCL2L1 | BCL2 1/4885BCL2L1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.